Trade Mark Journal No.2026/002 9 January 2026

WO0000001892893 (5)

Office of origin: United States of America

Date of International Registration:5 November 2025
Date of designation in the UK: 5 November 2025
Image for mark 1892893 NAVGENVYS

International priority date claimed: 6 May 2025 (United States of America) (99172007)
Class 5
Biological preparations for medical use in the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; pharmaceutical preparations for the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; clinical medical reagents for use in gene therapy; therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of genetic diseases and disorders, namely, Duchenne muscular dystrophy; gene therapy preparation for medical use containing genetic materials for sustained protein expression, namely, microdystrophin expression.

REGENXBIO Inc.

Representative: William R. Samuels Cole-Frieman & Mallon, LLP, 201 California street, Suite 350, San Francisco CA 94111, UNITED STATES OF AMERICA